Mens Health Diagnostics Market by Product Type (Imaging Systems, Laboratory Tests), End User (Ambulatory Surgical Centers, Clinics, Diagnostic Centers), Application - Global Forecast 2025-2032
Description
The Mens Health Diagnostics Market was valued at USD 14.59 billion in 2024 and is projected to grow to USD 16.27 billion in 2025, with a CAGR of 11.70%, reaching USD 35.39 billion by 2032.
A strategic introduction framing clinical, technological, and demographic forces that are redefining diagnostics, prevention, and care for men's health
Men's health diagnostics occupy a central role in modern healthcare as demographic shifts, evolving risk profiles, and technological advances combine to demand more precise, accessible, and patient-centric testing pathways. Historically, diagnostic strategies for male-specific and male-predominant conditions have prioritized early detection and risk stratification, but the contemporary landscape requires integration across imaging modalities, laboratory assays, and data-driven decision support to achieve meaningful clinical impact. Consequently, stakeholders across clinical care, device manufacturing, and laboratory services are re-evaluating pathways for screening, monitoring, and therapeutic planning.
This introduction situates the reader within that dynamic context by outlining core clinical drivers such as an aging population, rising prevalence of metabolic and cardiovascular conditions, and continued emphasis on prostate and urological disease detection. It also frames technological enablers including advanced imaging software, molecular assays, and remote monitoring tools that are converging to reshape diagnostic workflows. Moving forward, the interplay between clinical need, regulatory expectations, and payer alignment will determine adoption curves and the practical ability of healthcare systems to incorporate high-value diagnostic innovations into routine care.
Transformative shifts in diagnostics propelled by artificial intelligence, point-of-care testing expansion, biomarker innovation, and patient-centered integration
The diagnostic landscape is undergoing transformative shifts driven by the rapid maturation of artificial intelligence, the expansion of point-of-care testing, and continuous advances in molecular biomarkers. AI-enhanced image analysis is increasing the consistency and sensitivity of radiologic interpretation, enabling earlier detection of structural disease while reducing inter-operator variability. At the same time, molecular assays and biomarker platforms are moving beyond single-analyte tests toward multiplexed panels and companion diagnostics, offering richer biological context for precision medicine.
Equally important, point-of-care and decentralized testing models are changing care delivery by bringing diagnostics closer to patients and reducing time-to-result, which supports earlier clinical intervention. These technological changes are accompanied by shifts in clinical practice guidelines and evolving reimbursement frameworks that place greater emphasis on outcome-linked value. As a result, organizations that integrate digital tools, bridge imaging and laboratory data, and prioritize interoperability across clinical pathways are positioned to deliver more actionable, cost-conscious diagnostics that align with contemporary standards of care.
Analysis of how United States tariff changes in 2025 influence procurement, manufacturing resilience, and strategic sourcing across diagnostic supply chains
Tariff measures implemented by the United States in 2025 exert multi-dimensional effects across procurement, manufacturing resilience, and strategic sourcing choices within the diagnostic ecosystem. Import duties on certain devices, reagents, or components can alter supplier economics, leading providers to reassess supplier contracts and inventory practices. In turn, health systems and laboratories may experience pressure on operating budgets as procurement teams balance cost containment against the clinical imperative to maintain access to high-value diagnostic tools.
These policy-driven cost dynamics incentivize manufacturers to evaluate localization of production and nearshoring options to mitigate exposure to cross-border tariff volatility. Strategic responses include diversifying component sourcing, qualifying alternative suppliers, and optimizing supply chain visibility to reduce lead times and inventory risk. At the same time, procurement cycles may lengthen as organizations incorporate new total-cost analyses and compliance checks. Regulatory coordination, transparent communication from manufacturers, and proactive supply continuity planning will be critical to preserving consistent patient access to essential diagnostics while maintaining programmatic and capital investment timelines.
Deep segmentation insights highlighting product, end-user, and application nuances that guide targeted deployment and clinical adoption strategies
A nuanced segmentation lens reveals differentiated opportunities and operational considerations across product types, end users, and clinical applications. Product segmentation separates the market into imaging systems and laboratory tests; imaging systems encompass computed tomography, magnetic resonance imaging, nuclear imaging, ultrasound, and X-ray modalities, each presenting distinct capital, maintenance, and workflow integration demands, while laboratory tests split into biomarker assays and genetic testing that require varying laboratory infrastructure, analytical expertise, and regulatory pathways. End-user segmentation identifies ambulatory surgical centers, clinics, diagnostic centers, and hospitals as distinct channels with varying adoption drivers, procurement cycles, and service delivery models that materially influence product selection and implementation timelines. Application segmentation focuses attention on cardiovascular diagnostics, diabetes monitoring, prostate cancer diagnostics, and urological disorder diagnostics, each with unique clinical guidelines, longitudinal monitoring needs, and payer considerations.
When these segmentation dimensions intersect, they reveal specific deployment patterns: for example, imaging investments in hospitals favor high-throughput, advanced modalities with integrated analytics, whereas clinics and ambulatory centers prioritize compact, cost-efficient ultrasound or point-of-care laboratory platforms. Biomarker assays and genetic tests drive centralized laboratory models for complex analyses but also create demand for decentralized testing in diabetes monitoring, where immediacy of results alters care pathways. Understanding these cross-cutting segmentation dynamics is essential for designing clinical studies, crafting reimbursement narratives, and aligning product roadmaps with buyer expectations.
Regional dynamics and practical implications across established and emerging geographies that shape policy, reimbursement, and product localization decisions
Regional dynamics shape policy choices, reimbursement structures, and clinical adoption in ways that materially influence strategy and market access. In the Americas, health systems tend to emphasize value-based purchasing and integrated care models, creating demand for diagnostics that demonstrate clinical utility and pathway optimization. Reimbursement frameworks and payer engagement in this region often require robust real-world evidence and clear linkage to downstream clinical outcomes to secure favorable coverage decisions.
Europe, Middle East & Africa exhibit heterogeneous regulatory and payer landscapes where national-level policies and procurement norms vary widely; this diversity necessitates localized evidence generation and flexible commercial models. In several jurisdictions, centralized public procurement and stringent HTA processes drive an emphasis on cost-effectiveness and regional approvals. Asia-Pacific presents a mix of early-adopter markets and cost-sensitive environments, with several countries prioritizing rapid technology uptake and domestic manufacturing capacity. Across regions, successful localization strategies combine regulatory foresight, adaptive pricing approaches, and partnerships with local clinical networks to accelerate adoption while respecting regional policy and operational realities.
Competitive and corporate insights into innovation strategies, partnership models, regulatory navigation, and commercialization approaches for diagnostic providers
Corporate and competitive dynamics are shifting from product-centric competition toward ecosystem plays that combine platforms, services, and data capabilities. Market leaders are increasingly focused on strategic partnerships, acquisitions that expand laboratory or imaging capabilities, and investments in software that enable longitudinal patient monitoring and predictive analytics. These moves reflect a recognition that hardware alone is insufficient; integrated solutions that reduce clinician burden and demonstrate measurable clinical benefits are more likely to achieve durable adoption.
Regulatory navigation remains a core competency for companies seeking broad clinical deployment, requiring sustained engagement with agencies, compliance with evolving laboratory and device standards, and investment in clinical validation. Commercialization approaches are evolving to emphasize outcome-based contracting, bundled services, and collaborative pilots with health systems. Smaller innovators often pursue niche clinical applications to validate performance before scaling through partnerships or licensing. Across the competitive landscape, the ability to translate clinical evidence into payer-relevant outcomes while maintaining agile manufacturing and responsive post-market support differentiates the most successful organizations.
Actionable recommendations to help leaders accelerate innovation, strengthen supply resilience, and drive clinical adoption and payer alignment
Industry leaders should adopt pragmatic strategies that balance near-term operational resilience with long-term innovation pathways. First, firms must diversify supply chains and qualify alternate suppliers to reduce single-source failure risk while exploring regional manufacturing or assembly to minimize tariff and logistics exposure. At the same time, investing in digital capabilities-such as AI-assisted interpretation, laboratory information system interoperability, and secure data integration-will improve diagnostic throughput and clinician acceptance.
Organizations should also build stronger payer relationships by generating outcome-focused evidence and engaging in early dialogues to align coverage criteria with clinical endpoints. Collaborative pilots with health systems and diagnostic centers can create proof points that accelerate broader adoption. Finally, workforce training and clinical education programs are essential to ensure correct utilization and to maximize the value proposition of new diagnostics. By combining operational safeguards with focused investments in technology and stakeholder alignment, leaders can both protect continuity of care and position themselves for scalable innovation.
Rigorous research methodology outlining data sources, primary engagement, validation processes, and analytical frameworks supporting credibility and reproducibility
The report’s findings are grounded in a rigorous mixed-methods approach that combines primary stakeholder engagement, systematic review of peer-reviewed literature, and triangulation across regulatory filings and clinical guidelines. Primary inputs included structured interviews with clinicians, laboratory directors, procurement officers, and technology leaders, supplemented by expert roundtables that validated thematic findings and identified operational constraints. Secondary research encompassed analysis of scientific publications, device and assay documentation, and policy statements to ensure alignment with current clinical standards.
Analytical frameworks employed include qualitative thematic analysis, scenario mapping to test supply chain contingencies, and structured evidence grading for clinical utility. Quality controls included independent review of source materials, cross-validation of interview insights across stakeholder types, and iterative verification with domain experts. Together, these methods provide a transparent and reproducible foundation for the strategic insights presented in the report while acknowledging limitations inherent to evolving science and policy environments.
Concise and forward-looking conclusion synthesizing insights, strategic priorities, and implications for stakeholders across clinical, commercial, and policy domains
This synthesis highlights the intersection of clinical need, technological capability, and policy realities that will shape the future of men's health diagnostics. Key themes include the rise of integrated imaging and molecular approaches, the operational imperative of supply chain resilience in the face of policy shifts, and the necessity of payer-aligned evidence to drive adoption. Taken together, these elements point to a pragmatic path forward for stakeholders seeking to improve early detection, monitoring, and personalized care delivery in male-predominant disease areas.
Looking ahead, organizations that prioritize interoperable solutions, invest in clinical validation tied to meaningful outcomes, and maintain flexible commercial models will be best positioned to translate innovation into routine practice. Strategic collaboration across clinical, commercial, and policy domains will accelerate responsible adoption while protecting patient access and system sustainability. This conclusion underscores both the complexity of the landscape and the actionable opportunities for those who align technological investment with operational readiness and stakeholder engagement.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Imaging Systems
Computed Tomography
Magnetic Resonance Imaging
Nuclear Imaging
Ultrasound
X Ray
Laboratory Tests
Biomarker Assays
Genetic Testing
End User
Ambulatory Surgical Centers
Clinics
Diagnostic Centers
Hospitals
Application
Cardiovascular Diagnostics
Diabetes Monitoring
Prostate Cancer Diagnostics
Urological Disorder Diagnostics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Siemens Healthineers AG
Sysmex Corporation
bioMérieux SA
Becton Dickinson and Company
QIAGEN N.V.
DiaSorin S.p.A.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic introduction framing clinical, technological, and demographic forces that are redefining diagnostics, prevention, and care for men's health
Men's health diagnostics occupy a central role in modern healthcare as demographic shifts, evolving risk profiles, and technological advances combine to demand more precise, accessible, and patient-centric testing pathways. Historically, diagnostic strategies for male-specific and male-predominant conditions have prioritized early detection and risk stratification, but the contemporary landscape requires integration across imaging modalities, laboratory assays, and data-driven decision support to achieve meaningful clinical impact. Consequently, stakeholders across clinical care, device manufacturing, and laboratory services are re-evaluating pathways for screening, monitoring, and therapeutic planning.
This introduction situates the reader within that dynamic context by outlining core clinical drivers such as an aging population, rising prevalence of metabolic and cardiovascular conditions, and continued emphasis on prostate and urological disease detection. It also frames technological enablers including advanced imaging software, molecular assays, and remote monitoring tools that are converging to reshape diagnostic workflows. Moving forward, the interplay between clinical need, regulatory expectations, and payer alignment will determine adoption curves and the practical ability of healthcare systems to incorporate high-value diagnostic innovations into routine care.
Transformative shifts in diagnostics propelled by artificial intelligence, point-of-care testing expansion, biomarker innovation, and patient-centered integration
The diagnostic landscape is undergoing transformative shifts driven by the rapid maturation of artificial intelligence, the expansion of point-of-care testing, and continuous advances in molecular biomarkers. AI-enhanced image analysis is increasing the consistency and sensitivity of radiologic interpretation, enabling earlier detection of structural disease while reducing inter-operator variability. At the same time, molecular assays and biomarker platforms are moving beyond single-analyte tests toward multiplexed panels and companion diagnostics, offering richer biological context for precision medicine.
Equally important, point-of-care and decentralized testing models are changing care delivery by bringing diagnostics closer to patients and reducing time-to-result, which supports earlier clinical intervention. These technological changes are accompanied by shifts in clinical practice guidelines and evolving reimbursement frameworks that place greater emphasis on outcome-linked value. As a result, organizations that integrate digital tools, bridge imaging and laboratory data, and prioritize interoperability across clinical pathways are positioned to deliver more actionable, cost-conscious diagnostics that align with contemporary standards of care.
Analysis of how United States tariff changes in 2025 influence procurement, manufacturing resilience, and strategic sourcing across diagnostic supply chains
Tariff measures implemented by the United States in 2025 exert multi-dimensional effects across procurement, manufacturing resilience, and strategic sourcing choices within the diagnostic ecosystem. Import duties on certain devices, reagents, or components can alter supplier economics, leading providers to reassess supplier contracts and inventory practices. In turn, health systems and laboratories may experience pressure on operating budgets as procurement teams balance cost containment against the clinical imperative to maintain access to high-value diagnostic tools.
These policy-driven cost dynamics incentivize manufacturers to evaluate localization of production and nearshoring options to mitigate exposure to cross-border tariff volatility. Strategic responses include diversifying component sourcing, qualifying alternative suppliers, and optimizing supply chain visibility to reduce lead times and inventory risk. At the same time, procurement cycles may lengthen as organizations incorporate new total-cost analyses and compliance checks. Regulatory coordination, transparent communication from manufacturers, and proactive supply continuity planning will be critical to preserving consistent patient access to essential diagnostics while maintaining programmatic and capital investment timelines.
Deep segmentation insights highlighting product, end-user, and application nuances that guide targeted deployment and clinical adoption strategies
A nuanced segmentation lens reveals differentiated opportunities and operational considerations across product types, end users, and clinical applications. Product segmentation separates the market into imaging systems and laboratory tests; imaging systems encompass computed tomography, magnetic resonance imaging, nuclear imaging, ultrasound, and X-ray modalities, each presenting distinct capital, maintenance, and workflow integration demands, while laboratory tests split into biomarker assays and genetic testing that require varying laboratory infrastructure, analytical expertise, and regulatory pathways. End-user segmentation identifies ambulatory surgical centers, clinics, diagnostic centers, and hospitals as distinct channels with varying adoption drivers, procurement cycles, and service delivery models that materially influence product selection and implementation timelines. Application segmentation focuses attention on cardiovascular diagnostics, diabetes monitoring, prostate cancer diagnostics, and urological disorder diagnostics, each with unique clinical guidelines, longitudinal monitoring needs, and payer considerations.
When these segmentation dimensions intersect, they reveal specific deployment patterns: for example, imaging investments in hospitals favor high-throughput, advanced modalities with integrated analytics, whereas clinics and ambulatory centers prioritize compact, cost-efficient ultrasound or point-of-care laboratory platforms. Biomarker assays and genetic tests drive centralized laboratory models for complex analyses but also create demand for decentralized testing in diabetes monitoring, where immediacy of results alters care pathways. Understanding these cross-cutting segmentation dynamics is essential for designing clinical studies, crafting reimbursement narratives, and aligning product roadmaps with buyer expectations.
Regional dynamics and practical implications across established and emerging geographies that shape policy, reimbursement, and product localization decisions
Regional dynamics shape policy choices, reimbursement structures, and clinical adoption in ways that materially influence strategy and market access. In the Americas, health systems tend to emphasize value-based purchasing and integrated care models, creating demand for diagnostics that demonstrate clinical utility and pathway optimization. Reimbursement frameworks and payer engagement in this region often require robust real-world evidence and clear linkage to downstream clinical outcomes to secure favorable coverage decisions.
Europe, Middle East & Africa exhibit heterogeneous regulatory and payer landscapes where national-level policies and procurement norms vary widely; this diversity necessitates localized evidence generation and flexible commercial models. In several jurisdictions, centralized public procurement and stringent HTA processes drive an emphasis on cost-effectiveness and regional approvals. Asia-Pacific presents a mix of early-adopter markets and cost-sensitive environments, with several countries prioritizing rapid technology uptake and domestic manufacturing capacity. Across regions, successful localization strategies combine regulatory foresight, adaptive pricing approaches, and partnerships with local clinical networks to accelerate adoption while respecting regional policy and operational realities.
Competitive and corporate insights into innovation strategies, partnership models, regulatory navigation, and commercialization approaches for diagnostic providers
Corporate and competitive dynamics are shifting from product-centric competition toward ecosystem plays that combine platforms, services, and data capabilities. Market leaders are increasingly focused on strategic partnerships, acquisitions that expand laboratory or imaging capabilities, and investments in software that enable longitudinal patient monitoring and predictive analytics. These moves reflect a recognition that hardware alone is insufficient; integrated solutions that reduce clinician burden and demonstrate measurable clinical benefits are more likely to achieve durable adoption.
Regulatory navigation remains a core competency for companies seeking broad clinical deployment, requiring sustained engagement with agencies, compliance with evolving laboratory and device standards, and investment in clinical validation. Commercialization approaches are evolving to emphasize outcome-based contracting, bundled services, and collaborative pilots with health systems. Smaller innovators often pursue niche clinical applications to validate performance before scaling through partnerships or licensing. Across the competitive landscape, the ability to translate clinical evidence into payer-relevant outcomes while maintaining agile manufacturing and responsive post-market support differentiates the most successful organizations.
Actionable recommendations to help leaders accelerate innovation, strengthen supply resilience, and drive clinical adoption and payer alignment
Industry leaders should adopt pragmatic strategies that balance near-term operational resilience with long-term innovation pathways. First, firms must diversify supply chains and qualify alternate suppliers to reduce single-source failure risk while exploring regional manufacturing or assembly to minimize tariff and logistics exposure. At the same time, investing in digital capabilities-such as AI-assisted interpretation, laboratory information system interoperability, and secure data integration-will improve diagnostic throughput and clinician acceptance.
Organizations should also build stronger payer relationships by generating outcome-focused evidence and engaging in early dialogues to align coverage criteria with clinical endpoints. Collaborative pilots with health systems and diagnostic centers can create proof points that accelerate broader adoption. Finally, workforce training and clinical education programs are essential to ensure correct utilization and to maximize the value proposition of new diagnostics. By combining operational safeguards with focused investments in technology and stakeholder alignment, leaders can both protect continuity of care and position themselves for scalable innovation.
Rigorous research methodology outlining data sources, primary engagement, validation processes, and analytical frameworks supporting credibility and reproducibility
The report’s findings are grounded in a rigorous mixed-methods approach that combines primary stakeholder engagement, systematic review of peer-reviewed literature, and triangulation across regulatory filings and clinical guidelines. Primary inputs included structured interviews with clinicians, laboratory directors, procurement officers, and technology leaders, supplemented by expert roundtables that validated thematic findings and identified operational constraints. Secondary research encompassed analysis of scientific publications, device and assay documentation, and policy statements to ensure alignment with current clinical standards.
Analytical frameworks employed include qualitative thematic analysis, scenario mapping to test supply chain contingencies, and structured evidence grading for clinical utility. Quality controls included independent review of source materials, cross-validation of interview insights across stakeholder types, and iterative verification with domain experts. Together, these methods provide a transparent and reproducible foundation for the strategic insights presented in the report while acknowledging limitations inherent to evolving science and policy environments.
Concise and forward-looking conclusion synthesizing insights, strategic priorities, and implications for stakeholders across clinical, commercial, and policy domains
This synthesis highlights the intersection of clinical need, technological capability, and policy realities that will shape the future of men's health diagnostics. Key themes include the rise of integrated imaging and molecular approaches, the operational imperative of supply chain resilience in the face of policy shifts, and the necessity of payer-aligned evidence to drive adoption. Taken together, these elements point to a pragmatic path forward for stakeholders seeking to improve early detection, monitoring, and personalized care delivery in male-predominant disease areas.
Looking ahead, organizations that prioritize interoperable solutions, invest in clinical validation tied to meaningful outcomes, and maintain flexible commercial models will be best positioned to translate innovation into routine practice. Strategic collaboration across clinical, commercial, and policy domains will accelerate responsible adoption while protecting patient access and system sustainability. This conclusion underscores both the complexity of the landscape and the actionable opportunities for those who align technological investment with operational readiness and stakeholder engagement.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Imaging Systems
Computed Tomography
Magnetic Resonance Imaging
Nuclear Imaging
Ultrasound
X Ray
Laboratory Tests
Biomarker Assays
Genetic Testing
End User
Ambulatory Surgical Centers
Clinics
Diagnostic Centers
Hospitals
Application
Cardiovascular Diagnostics
Diabetes Monitoring
Prostate Cancer Diagnostics
Urological Disorder Diagnostics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Siemens Healthineers AG
Sysmex Corporation
bioMérieux SA
Becton Dickinson and Company
QIAGEN N.V.
DiaSorin S.p.A.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing adoption of AI-driven at-home testosterone and prostate cancer screening kits allowing real-time health monitoring
- 5.2. Rising popularity of personalized hormone profiling platforms offering tailored male wellness insights and treatment recommendations
- 5.3. Surge in telehealth integration with remote urology consults and diagnostics for improved accessibility in men's health care
- 5.4. Expansion of noninvasive liquid biopsy technologies for dynamic monitoring of prostate and testicular cancer progression
- 5.5. Increased demand for mobile app-based fertility testing combined with wearable data to support delayed fatherhood planning
- 5.6. Regulatory changes driving broader insurance coverage for advanced metabolic and cardiovascular diagnostic tests in men
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Mens Health Diagnostics Market, by Product Type
- 8.1. Imaging Systems
- 8.1.1. Computed Tomography
- 8.1.2. Magnetic Resonance Imaging
- 8.1.3. Nuclear Imaging
- 8.1.4. Ultrasound
- 8.1.5. X Ray
- 8.2. Laboratory Tests
- 8.2.1. Biomarker Assays
- 8.2.2. Genetic Testing
- 9. Mens Health Diagnostics Market, by End User
- 9.1. Ambulatory Surgical Centers
- 9.2. Clinics
- 9.3. Diagnostic Centers
- 9.4. Hospitals
- 10. Mens Health Diagnostics Market, by Application
- 10.1. Cardiovascular Diagnostics
- 10.2. Diabetes Monitoring
- 10.3. Prostate Cancer Diagnostics
- 10.4. Urological Disorder Diagnostics
- 11. Mens Health Diagnostics Market, by Region
- 11.1. Americas
- 11.1.1. North America
- 11.1.2. Latin America
- 11.2. Europe, Middle East & Africa
- 11.2.1. Europe
- 11.2.2. Middle East
- 11.2.3. Africa
- 11.3. Asia-Pacific
- 12. Mens Health Diagnostics Market, by Group
- 12.1. ASEAN
- 12.2. GCC
- 12.3. European Union
- 12.4. BRICS
- 12.5. G7
- 12.6. NATO
- 13. Mens Health Diagnostics Market, by Country
- 13.1. United States
- 13.2. Canada
- 13.3. Mexico
- 13.4. Brazil
- 13.5. United Kingdom
- 13.6. Germany
- 13.7. France
- 13.8. Russia
- 13.9. Italy
- 13.10. Spain
- 13.11. China
- 13.12. India
- 13.13. Japan
- 13.14. Australia
- 13.15. South Korea
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2024
- 14.2. FPNV Positioning Matrix, 2024
- 14.3. Competitive Analysis
- 14.3.1. F. Hoffmann-La Roche Ltd
- 14.3.2. Abbott Laboratories
- 14.3.3. Thermo Fisher Scientific Inc.
- 14.3.4. Danaher Corporation
- 14.3.5. Siemens Healthineers AG
- 14.3.6. Sysmex Corporation
- 14.3.7. bioMérieux SA
- 14.3.8. Becton Dickinson and Company
- 14.3.9. QIAGEN N.V.
- 14.3.10. DiaSorin S.p.A.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
